49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02102594 (ClinicalTrials.gov) | October 2014 | 25/3/2014 | Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) | Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) | Myasthenia Gravis;Systemic Lupus Erythematosus;Rheumatoid Arthritis | Drug: Bortezomib | Charite University, Berlin, Germany | Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology);NeuroCure Clinical Research Center, Charite, Berlin | Terminated | 18 Years | 75 Years | All | 11 | Phase 2 | Germany |
| 2 | JPRN-UMIN000012227 | 2013/11/06 | 06/11/2013 | A phase II randomized trial of evaluation for boltezomib in refractory Systemic lupus erythematosus | A phase II randomized trial of evaluation for boltezomib in refractory Systemic lupus erythematosus - A phase II randomized trial of evaluation for boltezomib in refractory Systemic lupus erythematosus | Systemic lupus erythmatosus | bortezomib(1.3mg/m2) 2times/week total 8times. saline | Tohoku university hospital | NULL | Complete: follow-up complete | 20years-old | 65years-old | Male and Female | 14 | Phase 2 | Japan |